- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-662/16: Judgment of the General Court of 3 May 2018 — Gall Pharma v EUIPO — Pfizer (Styriagra) (EU trade mark — Opposition proceedings — Application for EU word mark Styriagra — Earlier EU word mark VIAGRA — Taking unfair advantage of the distinctive character or repute of the earlier mark — Article 8(5) of Regulation (EC) No 207/2009 (now Article 8(5) of Regulation (EU) 2017/1001))
ECLI:EU:UNKNOWN:62016TA0662
62016TA0662
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
(Case T-662/16) (*1)
‛(EU trade mark — Opposition proceedings — Application for EU word mark Styriagra — Earlier EU word mark VIAGRA — Taking unfair advantage of the distinctive character or repute of the earlier mark — Article 8(5) of Regulation (EC) No 207/2009 (now Article 8(5) of Regulation (EU) 2017/1001))’
Language of the case: English
Parties
Applicant: Gall Pharma GmbH (Judenburg, Austria) (represented initially by: D. Reichelt and L. Figura, and subsequently by T. Schafft, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Gája and D. Walicka, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard and J. Fuhrmann, lawyers)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 13 June 2016 (Case R 724/2015-5), relating to opposition proceedings between Pfizer and Gall Pharma.
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Gall Pharma GmbH to pay the costs.
*
(*1) OJ C 441, 28.11.2016.